Newron Pharmaceuticals S.p.A.

Yes. Newron Pharmaceuticals (NWRN) has been listed on the SIX Swiss Exchange since 2006, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CHF. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

One Newron Pharmaceuticals share is CHF 8.14 — about ₹938 at a CHF/INR rate of 115.18 on 29 Sep 2026. Both the Newron Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CHF/INR rate on the purchase and the sale date, so the rupee move counts alongside the Newron Pharmaceuticals price. Paasa issues a capital-gains statement for your return.

No. Newron Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

The SIX Swiss Exchange trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Switzerland is on standard time. Orders can only execute during that window.

Newron Pharmaceuticals trades on the SIX Swiss Exchange in CHF, but the company is domiciled in Italy. Newron Pharmaceuticals trades as an ordinary share listed directly in Switzerland, not a depositary receipt. Your India-side capital-gains treatment is the same either way.

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Newron Pharmaceuticals holding, its cost and its closing value.

You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in CHF in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.

Yes. Newron Pharmaceuticals is priced in CHF, so your rupee outcome combines the CHF move with the CHF/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.